← Back to Home

Crossing the Blood-Brain Barrier: FDA Approves First Treatment for Neurological Symptoms of Type 3 Gaucher Disease

Even after their organ disease has stabilized, patients with type 3 Gaucher disease may still face worsening balance and cognitive difficulties. The newly approved oral drug venglustat offers an option for this treatment gap, but the limits of efficacy evidence from a small trial and psychiatric safety risks also require careful attention.

By SURL BioNews

For patients with type 3 Gaucher disease, controlling liver and spleen enlargement and anemia may not prevent progressive impairment of balance, coordination, and thinking abilities. On November 18, the U.S. Food and Drug Administration (FDA) approved Sanofi’s Infilbray (venglustat), making it the first drug for neurological symptoms in these patients, indicated for adults and children weighing at least 15 kilograms.

Gaucher disease is a rare inherited disorder in which an enzyme deficiency or dysfunction prevents patients from properly breaking down certain glycolipids, causing them to accumulate in organs and tissues. Type 3 also affects the brain and nervous system. Existing enzyme replacement therapies can address systemic manifestations but have difficulty crossing the blood-brain barrier. Venglustat can enter the brain and inhibits glucosylceramide synthase to reduce the production of the relevant lipids.

The phase 3 LEAP2MONO trial (NCT05222906), which supported the approval, enrolled 43 patients aged at least 12 years. According to *Pharmacy Times*, they had received enzyme replacement therapy for at least three years and had achieved treatment goals for their systemic disease. The randomized, double-blind study assigned patients to daily oral venglustat or intravenous enzyme replacement therapy every two weeks and compared treatment outcomes over 52 weeks.

The study assessed motor coordination and cognitive function together in a composite measure, using a modified Scale for the Assessment and Rating of Ataxia (SARA) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), respectively. At week 52, the venglustat group showed greater improvement on this composite measure than the control group. However, the composite result cannot be interpreted directly as improvement in every neurological function for every patient. The FDA announcement also did not provide sufficiently detailed data to show the extent of improvement in daily life.

Beyond neurological symptoms, maintaining existing control of organ and blood manifestations is also crucial. *Pharmacy Times* reported that venglustat met three of four key systemic secondary endpoints, including spleen volume, liver volume, and hemoglobin. In January of this year, Cerezyme’s U.S. labeling was expanded to include the non-central nervous system manifestations of type 3 Gaucher disease. This approval further extends the scope of treatment to neurological symptoms.

Safety risks accompany this progress. The FDA noted that common adverse reactions include gastrointestinal symptoms and mood-related effects, and serious psychiatric risks, including suicidal ideation and behavior, have been reported. Animal studies also suggest a potential risk related to visual clouding in younger patients and potential effects on fetal development from exposure during pregnancy. These animal findings cannot be directly equated with incidence rates in humans, but they are an important basis for assessing the drug’s risks.

This approval moves treatment for type 3 Gaucher disease another step forward, from controlling disease in the body’s organs toward addressing symptoms in the brain. The key evidence available still comes from a one-year comparison involving 43 patients, all aged at least 12 years, which does not fully match the pediatric population covered by the approval. Longer-term data are still needed to establish how long efficacy lasts, whether treatment can alter the long-term course of neurodegeneration, and the treatment experience in younger patients.

References

  1. FDA
  2. Pharmacy Times